enGene (NASDAQ:ENGN) Shares Gap Up to $14.85

enGene Holdings Inc. (NASDAQ:ENGN)’s stock price gapped up prior to trading on Monday . The stock had previously closed at $14.85, but opened at $15.49. enGene shares last traded at $15.00, with a volume of 3,243 shares traded.

Wall Street Analyst Weigh In

ENGN has been the topic of a number of research analyst reports. SVB Leerink initiated coverage on enGene in a research note on Tuesday, February 20th. They issued an “outperform” rating and a $31.00 price target on the stock. Morgan Stanley initiated coverage on enGene in a research note on Friday, March 8th. They issued an “overweight” rating and a $40.00 price target on the stock. Wells Fargo & Company initiated coverage on enGene in a research note on Monday. They issued an “overweight” rating and a $30.00 price target on the stock. UBS Group began coverage on enGene in a research note on Thursday, March 28th. They issued a “buy” rating and a $37.00 price target on the stock. Finally, Guggenheim began coverage on enGene in a research note on Monday, April 15th. They set a “buy” rating and a $34.00 price objective on the stock. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, enGene has an average rating of “Buy” and an average target price of $34.40.

enGene Stock Up 3.1 %

The business has a 50 day simple moving average of $16.27.

Insiders Place Their Bets

In other enGene news, major shareholder De Solidarite Des Travai Fonds sold 47,854 shares of enGene stock in a transaction on Monday, April 22nd. The stock was sold at an average price of $15.00, for a total value of $717,810.00. Following the sale, the insider now owns 3,036,153 shares in the company, valued at $45,542,295. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Institutional Investors Weigh In On enGene

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Fcpm Iii Services B.V. purchased a new stake in enGene in the fourth quarter valued at $80,097,000. BVF Inc. IL purchased a new stake in shares of enGene in the 4th quarter valued at $20,777,000. Omega Fund Management LLC purchased a new stake in shares of enGene in the 4th quarter valued at $10,441,000. Finally, Vivo Capital LLC purchased a new stake in shares of enGene in the 4th quarter valued at $6,264,000. Hedge funds and other institutional investors own 64.16% of the company’s stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.